ArticleInternational journal of chronic obstructive pulmonary disease2026
Identifying Biomarkers for Chronic Obstructive Pulmonary Disease in the Salivary Metabolome.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We compared salivary metabolomic signatures from patients with stable COPD across a range of severity of airflow obstruction with healthy controls. Patients and Methods: In this exploratory study, 47 people with COPD and 48 age-matched, healthy controls, provided saliva that was assessed by flow infusion electrospray mass spectrometry (FIE-MS). Spectra were interrogated using an open-source library DIMEpy package. Results: Four potential biomarkers identified the presence of COPD with a sensitivity of 73% and specificity of 72%. Six metabolites predicted the level of airflow obstruction, FEV1% in the COPD cohort ( Conclusion: This proof-of-concept study shows metabolic fingerprinting of saliva samples is feasible and can differentiate patients with COPD from people (including smokers) without COPD and correlates with COPD severity as defined by level of airflow obstruction. Metabolic fingerprinting also offers insights into the metabolic pathways involved in COPD aetiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.